Publications

Activity of Lefamulin, an Pleuromutilin Derivative, against S. aureus Strains with Decreased Susceptibility to Vancomycin, Lead author: Sader HS, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Ceftobiprole Activity When Tested Against Clinical Bacterial Pathogens from Europe, Turkey and Israel 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

In vitro activity of oritavancin against streptococci, including macrolide- and/or lincosamide (constitutive)-resistant and MDR isolates from EU hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Tigecycline activity tested against >11,000 isolates of Acinetobacter spp. collected worldwide in 2004-2013, Lead author: Sader HS, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Sustained potent activity of dalbavancin when tested against MDR staphylococcal and streptococcal isolates responsible for documented infection in EU (2011-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Debio 1452 MIC QC Range with S. aureus ATCC 29213 Using a Multi-laboratory Study Design, Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Accuracy of Predicting Oritavancin Susceptibility using Vancomycin Surrogate Susceptibility Testing of GP from EU, Lead author: Jones RN, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Minocycline activity tested against A. baumannii, B. cepacia, S. maltophila, and select Enterobacteriaceae isolates from a European surveillance program (2013), Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Update on dalbavancin activity tested against Gram-positive isolates causing documented skin and soft tissue infections in USA and European hospitals (2011-2013), Lead author: Medes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial potency of lefamulin (BC-3781) tested against S. pneumoniae with defined serotypes, including MDR isolates causing lower RTI in the USA, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Potent in vitro activity of telavancin against EU strep. isolates displaying an array of antibiogram profiles, Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Maximizing antibacterial activity of polymyxin B: Microbiological component analyses alone and in combination, Lead author: Kassamali Z, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Pseudomonas aeruginosa Isolates from 15 European Countries and Israel (2013), Lead author: Sader HS, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested against Enterobacteriaceae Isolates from 15 European Countries and Israel (2013), Lead author: Farrell DJ, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Molecular characterization of genes encoding CTX-M-134, TEM-207 and TEM-212 detected among Escherichia coli clinical isolates from USA hospitals, Lead author: Castanheira M, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

In vitro activity of dalbavancin tested against S. pneumoniae responsible for documented infection in medical centres in five continents worldwide (2011-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Oritavancin in vitro activity against the most prevalent antibiogram resistance patterns among MRSA, including MDR strains from patients in European hospitals (2010-2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Update of the telavancin in vitro activity against SA and CoNS, including isolates with decreasing susceptibility for comparator agents in European hospitals (2013), Lead author: Mendes RE, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). by Pfaller MA, Messer SA, Jones RN and Castanheira M. published in J. Antibiot. (Tokyo) 2015; 68 (9): 556-561

Activity of Debio1452, a FabI inhibitor with potent activity against S. aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. by Flamm RK, Rhomberg P, Kaplan N, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (5): 2583-2587

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056, 2015

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. by Sader HS, Flamm RK, Streit J, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2458-2461,

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. by Pfaller MA, Rhomberg PR, Messer SA and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 259-263

In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. by McCurdy SP, Jones RN, Mendes RE, Puttagunta S and Dunne MW published in Antimicrob. Agents Chemother. 2015; 59 (8): 5007-5009

Accuracy of the ThermoFisher Scientific (Sensititre^TM) dry-form broth microdilution MIC product when testing ceftaroline. by Jones RN, Holliday NM and Critchley IA. published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 280-282

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. by Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G and Newman JV published in Sci. Rep. 2015; 5: 11827

Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3263-3270

In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. by Flamm RK, Rhomberg PR, Jones RN and Farrell DJ published in Antimicrob. Agents Chemother. 2015; 59 (4): 2280-2285

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. by Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ and Jones RN. published in Int. J. Antimicrob. Agents. 2015; 46 (1): 53-59

Validation of Sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination. by Jones RN, Holliday NM and Krause KM published in Antimicrob. Agents Chemother. 2015; 59 (8): 5036-5039,

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in J. Global Antimicrob. Res. 2015; 3 (1): 36-39

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056,

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. by Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 283-289

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013). by Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ and Jones RN. published in Antimicrob. Agents Chemother.. 2015; 59 (6): 3656-3659

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013). by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2015; 70 (2): 498-504

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706

In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria. by Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF and Mueller JP published in Antimicrob. Agents Chemother. 2015; 59 (1): 467-474

Isavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: Temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. by Pfaller MA, Rhomberg PR, Messer SA, Jones RN and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2015; 82 (4): 303-313

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012. by Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2432-2434

Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1811-1814

In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. by Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1751-1754

Characterization of the novel DNA gyrase inhibitor AZD0914: Low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. by Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H and Mueller JP published in Antimicrob. Agents Chemother. 2015; 59 (3): 1478-1486

Validation of a commercial dry-form broth microdilution device (Sensititre®) for testing tedizolid, a new oxazolidinone. by Jones RN, Holliday NM and Rhomberg PR published in J. Clin. Microbiol. 2015; 53 (2): 657-659

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. by Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 78-84

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. by Stryjewski ME, Jones RN and Corey GR published in Diagn. Microbiol. Infect. Dis. 2015; 81 (3): 183-188

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. by Penwell WA, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband M, DeJonge BL, Ehmann DE and Miller AA published in Antimicrob. Agents Chemother. 2015; 59 (3): 1680-1689

Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. by Rose HR, Holzman RS, Altman DR, Smyth DS, Wasserman GA, Kafer JM, Wible M, Mendes RE, Torres VJ and Shopsin B published in J. Infect. Dis. 2015; 211 (12): 1862-1874

In vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas. by Waites KB, Crabb DM, Duffy LB and Huband MD published in Antimicrob. Agents. Chemother. 2015; 59 (6): 3627-3629